代用皮膚市場規模、成長と動向分析レポート 2026-2033年

代用皮膚市場規模、成長と動向分析レポート 2026-2033年

Skin Substitutes Market (2026 - 2033)

代用皮膚市場 - 製品(生物学的皮膚代替物、合成皮膚代替物)、用途(急性創傷、慢性創傷)、最終用途(病院、外来施設)、地域、セグメント別予測による市場規模、成長と動向分析レポート 2026-2033年

Skin Substitutes Market Size, Share & Trends Analysis Report By Product (Biological Skin Substitute, Synthetic Skin Substitute), By Application (Acute Wounds, Chronic Wounds), By End Use(Hospitals, Outpatient Facilities), By Region, And Segment Forecasts, 2026 - 2033


出版 Grand View Research
出版年月 2026年08月
ページ数 210
価格 記載以外のライセンスについてはお問合せください
 シングルユーザ USD 5,950
種別 英文調査報告書
商品番号 SMR-29195


SEMABIZ - otoiawase8

世界の代用皮膚市場の規模は2025年に19億米ドルと評価され、2026年の23億米ドルから2033年には49億米ドルへと、2026年から2033年にかけて年平均成長率(CAGR)11.7%で拡大するとGrand View Researchでは予測されています。2025年時点では、北米が41.3%という最大の収益シェアを占め、同市場を主導しました。世界の皮膚代替物市場の成長は、慢性創傷、糖尿病性足潰瘍、熱傷、および褥瘡(床ずれ)の有病率が世界的に増加していることによって牽引されています。

市場の主な動向とインサイト

  • 製品別:2025年、生物学的皮膚代替物セグメントが72.3%の収益シェアを占め、市場を主導しました。
  • 用途別:2025年、急性創傷セグメントが55.7%の収益シェアを占め、市場を主導しました。
  • 最終用途別:2025年、病院セグメントが54.9%の収益シェアを占め、市場を主導しました。

地域別のハイライト

  • 最大の地域市場:北米(2025年時点で収益シェア41.3%)
  • 最も急成長している市場:アジア太平洋地域(2026年~2033年の期間で最高のCAGRを記録)
  • 国別:2025年時点で米国が最大の市場シェアを占めました。

高度な創傷ケア製品の採用拡大、高齢者人口の増加、そして医療費の増大が、再生医療(再生療法)への需要を押し上げています。

糖尿病およびその合併症、とりわけ糖尿病性足潰瘍(DFU)の有病率の上昇は、皮膚代替物市場の成長を促す主要な要因となっています。糖尿病は、血流の低下、神経障害、感染症リスクの増大によって創傷治癒を阻害するため、高度な創傷ケア製品への需要が高まっています。米国および世界全体で糖尿病患者数が増加する中、組織修復を促進し切断のリスクを低減するための再生医療(生物学的および合成皮膚代替物を含む)を必要とする患者層も拡大しています。

製品別インサイト

代用皮膚(人工皮膚)市場において、生物学的皮膚代替物セグメントは2025年に市場全体の72.3%を占め、圧倒的なシェアを誇りました。この優位性は、慢性創傷、糖尿病性足潰瘍、静脈性下腿潰瘍、褥瘡、熱傷、および手術創の治療において、生物由来製品が広く使用されていることに裏打ちされています。これらの代替物は天然の皮膚を忠実に模倣し、細胞の増殖や組織の再生を促進するとともに、創傷治癒の迅速化や感染リスクの低減に寄与します。強力な臨床的エビデンス、先進国市場における有利な償還制度、そして生物学的創傷ケア製品に対する医師の選好の高まりが、同セグメントの市場における主導的地位をさらに強固なものにしています(2025年8月発表の調査による)。

用途別インサイト

代用皮膚(人工皮膚)市場においては、急性創傷の分野が市場の55.7%(2025年時点)を占め、圧倒的なシェアを誇っています。この優位性は、火傷、外傷性創傷、手術創、その他、迅速な創傷閉鎖や組織再生を必要とする急性皮膚損傷の症例数が多いことに裏打ちされています。皮膚代替物は、治癒の促進、感染リスクの低減、瘢痕(傷跡)の最小化、そして患者の回復改善を図るために、火傷治療センターや病院で広く使用されています。外傷や手術の症例数が増加していること、また火傷治療技術が進歩していることが、急性創傷管理における皮膚代替物の採用をさらに後押ししています。

エンドユーザー別インサイト

2025年の代用皮膚(人工皮膚)市場において、病院セグメントが54.9%のシェアを占め、市場を主導しました。この優位性は、火傷、外傷、慢性創傷、糖尿病性足潰瘍、複雑な手術創などの治療を必要とする患者数が多いことに起因しています。病院は、患者の治療成績を向上させ、高度な治療の選択肢を提供するために、専門的な創傷ケアユニット、火傷センター、および多職種連携による創傷管理プログラムの拡充を進めています。さらに、医療インフラへの投資拡大、病院ネットワークの拡大、そして高度な創傷ケアプロトコルの導入が進んでいることも、病院現場における生物学的および合成皮膚代替物の利用拡大を後押ししています。例えば、2025年10月には、KK Women’s and Children’s Hospital(KKH)が、小児に対する迅速かつ統合的な火傷治療を提供するため、シンガポール初となる小児専門の火傷センターを開設しました。同施設は、治療能力の強化、感染管理対策の改善、ケアプロセスの効率化を図り、より良好な回復結果の実現を支援しています。

本レポートでは、世界、地域、国別の収益成長を予測するとともに、2021年から2033年にかけての各サブセグメントにおける最新の業界動向を分析しています。本調査において、Grand View Researchは世界の代用皮膚市場を、製品、用途、最終用途、および地域に基づいて区分しています。

Skin Substitutes Market Summary

The global skin substitutes market size was valued at USD 1.9 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 4.9 billion by 2033, at a CAGR of 11.7% from 2026 to 2033. North America dominated the skin substitutes market with the largest revenue share of 41.3% in 2025. The growth of the global skin substitutes market is driven by the rising prevalence of chronic wounds, diabetic foot ulcers, burns, and pressure ulcers worldwide.

Key Market Trends & Insights

  • By product: Biological skin substitute segment led the market with the largest revenue share of 72.3% in 2025.
  • By application: Acute wounds segment led the market with the largest revenue share of 55.7% in 2025.
  • By end use: Hospitals segment led the market with the largest revenue share of 54.9% in 2025.

Regional Highlights

  • Largest regional market: North America (41.3% revenue share, 2025)
  • Fastest growing market: Asia Pacific (Fastest CAGR, 2026 – 2033)
  • By country: The U.S. held the largest market share in 2025

Market Size & Forecast

  • Market size in 2025: USD 1.9 Billion
  • Estimated market size in 2026: USD 2.3 Billion
  • Projected Market size by 2033: USD 4.9 Billion
  • CAGR(2026-2033): 11.7%

Increasing adoption of advanced wound care solutions, growing geriatric populations, and rising healthcare expenditure are driving demand for regenerative therapies.

The rising prevalence of diabetes and its associated complications, particularly diabetic foot ulcers (DFUs), is a major driver for the growth of the skin substitutes market. Diabetes impairs wound healing due to reduced blood circulation, neuropathy, and increased risk of infections, leading to a higher demand for advanced wound care solutions. The increasing number of diabetic patients across U.S. states and globally is expanding the patient pool requiring regenerative therapies, including biological and synthetic skin substitutes, to accelerate tissue repair and reduce amputation risks.

代用皮膚市場規模、成長と動向分析レポート 2026-2033年-market-size

skin-substitutes-market-size

For instance, according to the American Diabetes Association (ADA) (updated 2026, based on 2023 estimates), millions of adults in the U.S. are living with diagnosed diabetes, with states such as California, Texas, Florida, and New York reporting the highest number of affected individuals.

American Diabetes Association (ADA) State Fact Sheets and the CDC U.S. Diabetes Surveillance System

State Adult Diagnosed Diabetes (%) Approx. Adult Diagnosed Cases
Alabama 13.2% ~612,000
Alaska 9.0% ~53,000
Arizona 10.2% ~680,000
Arkansas 13.8% ~360,000
California 11.5% ~4.0 million
Colorado 7.8% ~420,000
Florida 9.8% ~2.2 million
Georgia 11.6% ~1.1 million
Illinois 11.4% ~1.2 million
Indiana 12.7% ~760,000
Kentucky 14.3% ~570,000
Louisiana 13.9% ~550,000
Michigan 11.8% ~1.0 million
Mississippi 13.2% ~370,000
New Jersey 9.2% ~800,000
New York 10.8% ~1.9 million
North Carolina 11.5% ~1.2 million
Ohio 11.3% ~1.2 million
Pennsylvania 11.6% ~1.3 million
South Carolina 11.7% ~650,000
Tennessee 12.7% ~820,000
Texas 12.9% ~3.1 million
Utah 8.8% ~240,000
Virginia 11.4% ~900,000
Washington 9.0% ~650,000
West Virginia 15.6% ~260,000

Centers for Medicare & Medicaid Services (CMS) 2026 Reimbursement Reform Impact on Skin Substitute Adoption and Market Dynamics

The implementation of CMS’s revised skin substitute reimbursement framework in 2026 is expected to significantly influence the U.S. skin substitutes market by reshaping pricing structures, product selection, and reimbursement accessibility. CMS introduced a standardized payment methodology, establishing a fixed reimbursement rate of approximately USD 127.14 per square centimeter for most cellular and tissue-based products (CTPs), while maintaining ASP-based reimbursement for licensed biological products. The policy emphasizes evidence-based product coverage, favoring skin substitutes with strong clinical validation and potentially impacting manufacturers with limited clinical data.

CMS categorized skin substitute products based on clinical evidence, with 18 products placed in Group 1 (Covered List). These products demonstrated strong clinical data supporting their effectiveness and will receive Medicare coverage under the updated reimbursement framework.

Covered Skin Substitute Products (Group 1)
HCPCS Code Product Name Company
Q4101 Apligraf Organogenesis
Q4186 Epifix MIMEDX Group
Q4106 Dermagraft Organogenesis
Q4133 Grafix Prime Smith & Nephew
A2019 Kerecis Omega3 MariGen Shield Kerecis
Q4105 Integra / Omniograft Integra LifeSciences
Q4102 Oasis Wound Matrix Smith & Nephew
Q4121 Theraskin LifeNet Health
Q4187 Epicord MIMEDX Group
Q4110 Primatrix Integra LifeSciences
Q4107 Graftjacket Stryker
Q4122 DermACELL Stryker / LifeNet
Q4128 FlexHD / Allopatch HD MTF Biologics
Q4151 Amnioband / Guardian MTF Biologics
Q4158 Kerecis Omega3 Kerecis
Q4159 Affinity Organogenesis
Q4160 NuShield Organogenesis
Q4203 Derma-Gide Geistlich / Stimlab
代用皮膚市場規模、成長と動向分析レポート 2026-2033年-human-medical-billing

skin-substitutes-market-human-medical-billing

Medicare coverage for skin substitutes depends on meeting specific clinical requirements, including the presence of eligible chronic wounds such as diabetic foot ulcers or venous leg ulcers, documentation of medical necessity, failure of standard wound care therapies, and the use of products supported by sufficient clinical evidence. The updated CMS framework emphasizes evidence-based reimbursement and prioritizes coverage for skin substitutes demonstrating proven clinical effectiveness.

Market Dynamics

Driver: Increasing prevalence of chronic wounds

The rising number of patients with chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and non-healing surgical wounds, is a major driver of the skin substitutes market. The growing prevalence of diabetes, obesity, and an aging population has increased the demand for advanced wound care products that accelerate healing and reduce complications. Skin substitutes help promote tissue regeneration, lower the risk of infection, and improve clinical outcomes, leading to their increasing adoption in hospitals, wound care centers, and specialty clinics.

Restraint: High cost of skin substitute products

The high cost of skin substitute products remains a key challenge for market growth. Bioengineered and regenerative skin substitutes require advanced manufacturing processes, specialized materials, and strict regulatory compliance, resulting in higher prices than conventional wound dressings. Limited reimbursement in some countries and budget constraints among healthcare providers may reduce product adoption, particularly in developing regions where affordability remains a significant concern.

Opportunity: Expansion of manufacturing and distribution facilities

The expansion of manufacturing and distribution facilities is creating significant growth opportunities for the skin substitutes market. Companies are investing in new production plants, expanding existing manufacturing capacities, and strengthening regional distribution networks to meet the rising global demand for advanced wound care products. These investments help improve product availability, reduce supply chain disruptions, and shorten delivery times for healthcare providers. Expansion into emerging markets across Asia-Pacific, Latin America, and the Middle East is also increasing patient access to innovative skin substitutes. As manufacturers scale production and improve distribution efficiency, they are expected to strengthen market penetration, support product adoption, and drive long-term revenue growth.

Market Concentration & Characteristics

The skin substitutes market is experiencing steady growth due to the rising prevalence of chronic wounds, burn injuries, diabetic foot ulcers, venous leg ulcers, and pressure ulcers, coupled with the increasing demand for advanced wound care solutions. Skin substitutes provide temporary or permanent coverage that promotes tissue regeneration, accelerates wound healing, reduces infection risk, and minimizes scarring compared with conventional wound dressings. The market is further supported by continuous advancements in bioengineered skin, acellular dermal matrices, synthetic skin substitutes, stem cell-based therapies, and regenerative medicine technologies, which improve clinical outcomes and reduce healing time. In addition, the growing aging population, increasing incidence of diabetes and obesity, rising adoption of minimally invasive wound management, expansion of specialized wound care centers and burn units, and ongoing investments in tissue engineering and biomaterials are driving market growth.

The skin substitutes market is characterized by a high degree of innovation, driven by continuous advancements in tissue engineering, regenerative medicine, biomaterials, and biofabrication technologies. Manufacturers are developing next-generation biological and synthetic skin substitutes with improved biocompatibility, enhanced tissue regeneration, faster wound healing, and reduced infection risk. Innovations such as acellular dermal matrices, bioengineered skin, stem cell-based therapies, and 3D bioprinting are improving clinical outcomes while expanding the range of applications for chronic wounds, burns, and reconstructive procedures.

The skin substitutes market has witnessed moderate to high merger and acquisition activity, as leading wound care and regenerative medicine companies continue expanding their product portfolios and geographic presence. Companies are acquiring tissue engineering firms, biologics manufacturers, and advanced wound care businesses to strengthen their offerings in biological skin substitutes, regenerative therapies, and wound management solutions. These strategic acquisitions help manufacturers broaden their product portfolios, enhance innovation capabilities, and expand access to new markets. For instance, in April 2026,  Made Scientific partnered with Regenicin to advance NovaDerm, an autologous cultured skin substitute, toward FDA approval for treating severe burns and chronic wounds. Made Scientific will provide GMP clinical manufacturing support to enable Regenicin’s IND submission and upcoming clinical trials for the regenerative skin therapy.

Skin substitute products are regulated as medical devices, biologics, or human tissue-based products, making regulatory compliance an important factor influencing product development and commercialization. Manufacturers must comply with stringent requirements related to product safety, quality, sterility, manufacturing processes, clinical evidence, and post-market surveillance. In major markets such as the U.S. and Europe, obtaining regulatory approvals from agencies such as the FDA and compliance with the European Medical Device Regulation (MDR 2017/745) are essential before commercialization. While these requirements increase development costs and approval timelines, they help ensure product safety, quality, and clinical effectiveness.

The skin substitutes market faces moderate competition from conventional wound care products, including wound dressings, hydrocolloids, foam dressings, alginate dressings, collagen dressings, and skin grafting procedures. These alternatives are commonly used for routine wound management because they are generally more affordable and widely available. However, for complex chronic wounds, severe burns, and difficult-to-heal ulcers, skin substitutes remain the preferred treatment option due to their ability to promote tissue regeneration, accelerate healing, and improve long-term clinical outcomes.

Demand for skin substitutes is highly concentrated among hospitals, specialized wound care centers, burn centers, ambulatory surgical centers, and specialty clinics. Hospitals and dedicated wound care centers account for the largest share of product utilization due to the high volume of patients requiring treatment for chronic wounds, burns, traumatic injuries, and complex surgical wounds. Growing adoption of advanced wound care protocols and multidisciplinary wound management programs continues to increase the use of biological and synthetic skin substitutes, making these healthcare facilities key contributors to overall market growth.

Product Insights

The biological skin substitute segment dominated the skin substitutes market, accounting for 72.3% of the market in 2025. This dominance is supported by the widespread use of biologically derived products in the treatment of chronic wounds, diabetic foot ulcers, venous leg ulcers, pressure ulcers, burns, and surgical wounds. These substitutes closely mimic natural skin, promote cell growth and tissue regeneration, support faster wound healing, and reduce the risk of infection. Strong clinical evidence, favorable reimbursement in developed markets, and increasing physician preference for biologic wound care products have further strengthened the segment’s leading market position. According to the study published in August 2025.

Study Highlights: Biological Skin Substitutes in Pressure Ulcers (2025)

  • A 2025 randomized controlled trial compared high-purity Type I collagen (HPTC) and dehydrated human amnion/chorion membrane (dHACM) in 80 patients with Stage III-IV pressure ulcers.
  • HPTC achieved higher complete wound closure (75%) compared with dHACM (62.5%) after seven weeks.
  • The findings supported collagen-based biological skin substitutes as a promising option for improving healing outcomes in complex pressure ulcers.

The synthetic skin substitute segment in the skin substitutes market is expected to grow at the fastest rate during the forecast period due to the increasing demand for cost-effective, durable, and readily available wound care solutions. Synthetic skin substitutes offer a longer shelf life, consistent product quality, lower risk of disease transmission, and easier storage compared to biological products. Continuous advancements in biomaterials and polymer technologies are improving their performance, making them suitable for burn care, trauma management, and chronic wound treatment, particularly in healthcare facilities seeking scalable and standardized wound care solutions.

Application Insights

The acute wounds segment dominated the skin substitutes market, accounting for 55.7% of the market in 2025. This dominance is supported by the high volume of burn injuries, traumatic wounds, surgical wounds, and other acute skin injuries requiring immediate wound closure and tissue regeneration. Skin substitutes are widely used in burn centers and hospitals to accelerate healing, reduce infection risk, minimize scarring, and improve patient recovery. Increasing numbers of trauma cases, surgical procedures, and advancements in burn care have further strengthened the adoption of skin substitutes for acute wound management.

The chronic wounds segment in the skin substitutes market is expected to grow at the fastest rate during the forecast period due to the rising prevalence of diabetic foot ulcers, venous leg ulcers, and pressure ulcers associated with the growing aging population and increasing incidence of diabetes and obesity. In October 2025, according to the Mölnlycke Health Care.

Venous Leg Ulcers: Key Clinical Insights and Disease Burden

  • VLUs affect approximately 1% of the general population and around 4% of people aged above 65 years in Australia.
  • Around 56% of VLUs recur within 3 months after wound closure, highlighting the need for long-term management and preventive care.
  • Venous leg ulcers are primarily caused by chronic venous insufficiency, where impaired blood flow and increased venous pressure delay wound healing.
  • The growing burden of VLUs is linked to ageing populations, obesity, chronic illnesses, and lifestyle-related risk factors.

End Use Insights

The hospitals segment dominated the skin substitutes market, accounting for 54.9% in 2025. This dominance is driven by the high volume of patients requiring treatment for burns, traumatic injuries, chronic wounds, diabetic foot ulcers, and complex surgical wounds. Hospitals are expanding specialized wound care units, burn centers, and multidisciplinary wound management programs to improve patient outcomes and provide advanced treatment options. In addition, increasing investments in healthcare infrastructure, expansion of hospital networks, and greater adoption of advanced wound care protocols are supporting the wider use of biological and synthetic skin substitutes across hospital settings. For instance, in October 2025, KK Women’s and Children’s Hospital (KKH) launched Singapore’s first dedicated paediatric Burn Centre to provide faster and more integrated burn care for children. The facility enhanced treatment capacity, improved infection control measures, and streamlined care processes to support better recovery outcomes.

  • KKH treated up to 400 new paediatric burn injury cases annually, with case numbers remaining stable over the past five years.
  • Infants and toddlers aged two years and below were the most vulnerable group, accounting for 50% of burn cases.
  • Children aged 5-10 years represented around 17% of cases, making them another high-risk group.
  • In 2024, the leading cause of childhood burns was scald injuries (71%) from hot water, soups, and beverages.
  • Contact burns accounted for 19% of cases, commonly caused by irons, hair curlers, pot covers, and oven doors.
  • Friction burns contributed 5% of injuries, mainly associated with treadmills and road traffic accidents.
代用皮膚市場規模、成長と動向分析レポート 2026-2033年-market-share

skin-substitutes-market-share

The research and manufacturing segment of the skin substitutes market is expected to grow at the fastest rate during the forecast period. Growth is driven by increasing investments in tissue engineering, regenerative medicine, and biomaterials research, along with collaborations between manufacturers, research institutions, and healthcare organizations to develop advanced skin substitute technologies. Companies are expanding manufacturing facilities, increasing production capacity, and investing in clinical research to improve product effectiveness and scalability. Strategic partnerships, technology collaborations, and funding initiatives are further supporting innovation and accelerating the commercialization of next-generation biological and synthetic skin substitutes.

Regional Insights 

The North America skin substitutes market held the largest revenue share in 2025 due to the region’s well-established advanced wound care infrastructure, high adoption of regenerative medicine products, and strong reimbursement support for chronic wound treatment. The presence of leading manufacturers, specialized wound care centers, and burn treatment facilities continues to support product adoption. Increasing clinical use of biological and synthetic skin substitutes for diabetic foot ulcers, burns, and complex surgical wounds is further strengthening market growth.

代用皮膚市場規模、成長と動向分析レポート 2026-2033年-by-region

skin-substitutes-market-trends-by-region

U.S. Skin Substitutes Market Trends

The U.S. skin substitutes market is witnessing significant growth due to the increasing availability of specialized wound care programs, strong adoption of advanced biologic therapies, and expanding outpatient wound management services. Hospitals and wound care centers are incorporating skin substitutes into treatment protocols to improve healing outcomes and reduce hospital stays. For instance, in September 2025, Smith+Nephew launched the CENTRIO Platelet-Rich-Plasma (PRP) System in the U.S. to expand its Advanced Wound Bioactives portfolio. The autologous PRP-based therapy was designed to support healing of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, through point-of-care application in hospital and physician office settings.

Europe Skin Substitutes Market Trends

The Europe skin substitutes market is experiencing steady growth due to increasing investments in advanced wound care, strong healthcare systems, and growing adoption of regenerative medicine across Germany, France, Italy, Spain, and the UK. The region benefits from well-established clinical guidelines for chronic wound management, increasing use of bioengineered skin products, and collaboration between healthcare providers and research institutions. Growing awareness of evidence-based wound care is also supporting market expansion.

The UK skin substitutes market is witnessing steady growth due to the increasing focus on reducing the burden of chronic wounds within the National Health Service (NHS). Hospitals and community healthcare providers are adopting advanced wound care products to improve healing rates, reduce treatment costs, and shorten recovery times. Ongoing investments in wound care services and the growing use of multidisciplinary wound management programs are further supporting market growth.

Asia Pacific Skin Substitutes Market Trends

The Asia Pacific skin substitutes market is expected to witness the fastest growth during the forecast period. Growth is supported by improving healthcare infrastructure, expanding access to advanced wound care, and increasing investments in burn care and specialty hospitals. Rising healthcare expenditure, growing awareness among healthcare professionals, and expansion of private healthcare providers are improving access to biological and synthetic skin substitutes. Local manufacturing activities and increasing regulatory approvals are also supporting regional market growth.

The China skin substitutes market is witnessing strong growth due to rapid expansion of the biotechnology and regenerative medicine industries, increasing domestic manufacturing capabilities, and government initiatives supporting healthcare modernization. Hospitals are adopting advanced wound care products to improve treatment outcomes, while local manufacturers are expanding production and developing cost-effective skin substitute technologies, improving product accessibility across the country.

Latin America Skin Substitutes Market Trends

The Latin America skin substitutes market is expected to witness strong growth due to improving access to advanced wound care services and increasing investments in public and private healthcare facilities. Countries such as Brazil and Argentina are expanding specialized wound care clinics and burn treatment centers, supporting greater adoption of skin substitutes. Rising awareness among healthcare professionals and improving availability of advanced wound care products are further contributing to market growth.

MEA Skin Substitutes Market Trends

The Middle East & Africa skin substitutes market is witnessing steady growth due to ongoing investments in healthcare infrastructure and the expansion of specialized burn care and wound management services. Countries including Saudi Arabia, the UAE, and South Africa are strengthening hospital capabilities and increasing access to advanced wound care technologies. The growing presence of international manufacturers and distributors, along with efforts to improve treatment standards for chronic wounds and burn injuries, is expected to support continued market expansion across the region.

Key Skin Substitutes Company Insights

Some of the key companies in the skin substitutes market include Organogenesis, Inc., PolyNovo Limited, Integra LifeSciences Corporation, Smith+Nephew, Tissue Regenix, RenovoDerm (ParaGen Technologies), MIMEDX Group, Inc., PolyMedics Innovations GmbH, GUNZE LIMITED, and Zimmer Biomet. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as product launch, and partnerships with other major companies.

代用皮膚市場規模、成長と動向分析レポート 2026-2033年-companies

skin-substitutes-market-key-skin-substitute-companies

Key Skin Substitutes Companies

The following key companies have been profiled for this study on the skin substitutes market:

  • Organogenesis, Inc.
  • PolyNovo Limited
  • Integra LifeSciences Corporation
  • Smith+Nephew
  • Tissue Regenix
  • RenovoDerm (ParaGen Technologies)
  • MIMEDX Group, Inc.
  • Essity Health & Medical. (Essity Aktiebolag (publ))
  • Stryker
  • Vericel Corporation
  • BioTissue (BioStem Technologies)
  • PolyMedics Innovations GmbH
  • GUNZE LIMITED
  • Zimmer Biomet

Competitive Benchmarking

Category Operating

Strategies

Competitive Edge Weakness
Established Players (Organogenesis, Inc., Integra LifeSciences Corporation, Smith+Nephew)
  • Focus on developing advanced biological and synthetic skin substitutes, expanding regenerative medicine portfolios, and strengthening clinical evidence through research and clinical studies.
  • Expand global presence through strategic partnerships with hospitals, wound care centers, distributors, and healthcare providers.
  • Strong global brand recognition, extensive R&D capabilities, broad advanced wound care portfolios, established distribution networks, and strong regulatory expertise.
  • Comprehensive clinical data, manufacturing scale, and global commercial presence enable these companies to maintain leadership in the skin substitutes market.
  • High product development and manufacturing costs, lengthy regulatory approval processes, and premium product pricing may limit adoption in cost-sensitive markets.
  • Increasing competition from emerging regenerative medicine companies.
Emerging Players (ParaGen Technologies), Vericel Corporation, BioTissue (BioStem Technologies))
  • Focus on developing innovative bioengineered, synthetic, and tissue-engineered skin substitutes with improved healing performance.
  • Expand manufacturing capabilities, obtain international regulatory approvals, and strengthen regional distribution partnerships.
  • Innovative technologies, specialized product portfolios, faster product development, and strong expertise in regenerative medicine enable these companies to address unmet clinical needs.
  • Competitive offerings and expansion into emerging markets support increasing market presence.
  • Lower global brand recognition, comparatively smaller sales and distribution networks, limited manufacturing scale, and lower marketing resources than established competitors.
  • Dependence on regional partnerships and regulatory approvals may slow international expansion and market penetration.

Recent Developments

  • In July 2026, INTENT Biologics received FDA Breakthrough Therapy designation for PEP Biologic for the treatment of diabetic foot ulcers (DFUs) under IND 019567. The designation supported accelerated development and regulatory review of its platelet-derived exosome-based biologic therapy for advanced wound care applications.
  • In November 2025, CMS announced a new skin substitute payment methodology in the CY 2026 Medicare Physician Fee Schedule Final Rule. The updated model set a volume-weighted average payment rate of approximately USD127.28 per square centimeter for most skin substitute products used in Medicare Part B wound care procedures, while licensed biological products continued under the ASP payment methodology.
  • In November 2025, Integra LifeSciences supported CMS’s 2026 Medicare reimbursement updates, which included its skin substitute portfolio such as Integra, PriMatrix, Cytal, and AmnioExcel. The policy advancement is expected to improve Medicare beneficiary access to Integra’s dermal regenerative templates and tissue-based wound care technologies.

Skin Substitutes Market Report Scope

Report Attribute Details
Market size in 2025 USD 1.9 billion
Estimated market size in 2026 USD 2.3 billion
Projected market size by 2033 USD 4.9 billion
Growth rate CAGR of 11.7% from 2026 to 2033
Base year for estimation 2025
Actual estimates/Historical data 2021 – 2024
Forecast period 2026 – 2033
Quantitative units Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Product, application, end use, and region
Regional scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Thailand; Australia; South Korea; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled Organogenesis, Inc.; PolyNovo Limited; Integra LifeSciences Corporation; Smith+Nephew; Tissue Regenix; RenovoDerm (ParaGen Technologies); MIMEDX Group, Inc.; Essity Health & Medical. (Essity Aktiebolag (publ)); Stryker; Vericel Corporation; BioTissue (BioStem Technologies); PolyMedics Innovations GmbH; GUNZE LIMITED; Zimmer Biomet
Customization scope Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope

Global Skin Substitutes Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin substitutes market report based on product, application, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 – 2033)
    • Biological Skin Substitute
      • Human Donor Tissue-derived Products
      • Acellular Animal-derived Products
    • Synthetic Skin Substitute
  • Application Outlook (Revenue, USD Million, 2021 – 2033)
    • Acute Wounds
    • Chronic Wounds
  • End Use Outlook (Revenue, USD Million, 2021 – 2033)
    • Hospitals
    • Outpatient Facilities
    • Research and Manufacturing
  • Regional Outlook (Revenue, USD Million, 2021-2033)
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Denmark
      • Sweden
      • Norway
    • Asia Pacific
      • Japan
      • China
      • India
      • Thailand
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Kuwait

Research Methodology

The skin substitutes market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each skin substitutes segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Segment – Product Revenue capture definition
Biological Skin Substitute Revenue is generated from products derived from human, animal, or bioengineered tissues that support wound healing by promoting cell growth, tissue regeneration, and vascularization. These products are widely used in the treatment of chronic wounds, burns, diabetic foot ulcers, venous leg ulcers, and complex surgical wounds.
Synthetic Skin Substitute Revenue is generated from products made using synthetic polymers and engineered biomaterials designed to provide temporary or permanent wound coverage. These substitutes protect the wound, maintain a moist healing environment, reduce infection risk, and support tissue regeneration in the management of burns, trauma, and chronic wounds.

The skin substitutes market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each skin substitutes segment quantified using the revenue-capture definitions in the table below.

Estimation Model  

Bottom-Up Estimation Top-Down Approach Supply-Side Analysis
The market is estimated by analyzing the annual volume of patients treated for chronic wounds, diabetic foot ulcers, venous leg ulcers, pressure ulcers, burns, traumatic wounds, and surgical wounds across hospitals, wound care centers, burn centers, ambulatory surgical centers, and specialty clinics at the country, regional, and global levels. The assessment incorporates the utilization of biological and synthetic skin substitutes and healthcare provider adoption patterns to derive the overall market value. The market estimation begins with an assessment of the global advanced wound care and regenerative medicine market, followed by evaluating the share contributed by skin substitutes through secondary research and expert validation. The analysis considers key market indicators such as the prevalence of chronic wounds and burns, the incidence of diabetes and obesity, the aging population, healthcare expenditure, and the adoption of advanced wound care technologies across major healthcare markets. The analysis considers manufacturing capacity, annual product shipments, product portfolio diversification (biological and synthetic skin substitutes), manufacturing facilities, average selling prices, and regional distribution networks. In addition, factors such as strategic collaborations with hospitals and wound care centers, product launches, clinical evidence, and production expansion are evaluated.

Delivered Customizations

This report has been delivered with the following In-depth customizations 

Client Request Customization Delivered Value Adds
Skin Substitutes Product Portfolio & Clinical Application Analysis Conducted a comprehensive assessment of the skin substitutes product portfolio, including biological and synthetic skin substitutes. Evaluated product adoption across key clinical applications such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, burns, traumatic wounds, and surgical wounds. The analysis also assessed product utilization across hospitals, burn centers, wound care clinics, and ambulatory surgical centers while identifying trends in biologic versus synthetic product preference, treatment protocols, and procedure-specific product selection. Helps stakeholders identify high-growth product segments, understand application-wise demand, evaluate treatment trends, and optimize product portfolios based on evolving clinical requirements and wound management practices.
End-user Adoption & Procurement Landscape Analysis Analyzed the adoption of skin substitutes across hospitals, specialty wound care centers, burn centers, ambulatory surgical centers, and specialty clinics. Assessed procurement practices, purchasing criteria, reimbursement influence, supplier selection, inventory management, and product preference for biological versus synthetic skin substitutes. The study also evaluated regional demand patterns and the impact of healthcare infrastructure, chronic wound prevalence, and advanced wound care programs on product adoption. Enables manufacturers to strengthen commercial strategies, identify high-demand end-user segments, optimize distribution networks, improve procurement planning, and expand market penetration across developed and emerging markets.
Product Positioning & Manufacturer Competitiveness Assessment Evaluated leading skin substitute manufacturers based on product portfolio breadth, biological and synthetic technologies, regenerative medicine capabilities, manufacturing capacity, geographic presence, pricing strategies, regulatory approvals, clinical evidence, and distribution strength. The assessment also analyzed recent product launches, manufacturing expansion, innovation in tissue engineering, strategic collaborations, and competitive differentiation across the global skin substitutes market. Supports competitive benchmarking, identifies product development opportunities, strengthens product positioning, improves commercialization strategies, and helps companies expand their presence through innovation, manufacturing scale, regulatory excellence, and entry into high-growth wound care markets.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Product
1.1.2. Application
1.1.3. End Use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.5. Details of primary research
1.5.1. Data for primary interviews in North America
1.5.2. Data for primary interviews in Europe
1.5.3. Data for primary interviews in Asia Pacific
1.5.4. Data for primary interviews in Latin America
1.5.5. Data for Primary interviews in MEA
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.1.1. Approach 1: Commodity flow approach
1.7.2. Volume price analysis (Model 2)
1.7.2.1. Approach 2: Volume price analysis
1.8. Research Scope and Assumptions
1.8.1. List of Secondary Sources
1.8.2. List of Primary Sources
1.8.3. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Skin Substitutes Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Increasing prevalence of chronic wounds
3.2.1.2. Technological advancements in skin substitutes
3.2.1.3. Rising geriatric population across the globe
3.2.1.4. Increasing surgical procedures
3.2.1.5. Growing burn and trauma cases
3.2.2. Market Restraints Analysis
3.2.2.1. High cost of skin substitute products
3.2.3. Market Opportunity Analysis
3.2.3.1. Rising distribution agreement for skin substitutes
3.2.3.2. Expansion of manufacturing and distribution facilities
3.2.3.3. Growing demand for aesthetic procedures
3.2.3.4. Expansion in emerging markets
3.2.4. Market Challenge Analysis
3.2.4.1. Intense competition
3.3. Skin Substitutes Market Analysis Tools
3.3.1. Porter’s Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental landscape
3.3.2.5. Legal landscape
Chapter 4. Skin Substitutes Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Skin Substitutes Market: Product Movement Analysis, 2025 & 2033 (USD Million)
4.3. Global Skin Substitutes Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Biological Skin Substitute
4.4.1. Biological skin substitute market revenue estimates and forecasts, 2021 – 2033 (USD Million)
4.4.2. Human Donor Tissue-derived Products
4.4.2.1. Human donor tissue-derived products market revenue estimates and forecasts, 2021 – 2033 (USD Million)
4.4.3. Acellular Animal-derived Products
4.4.3.1. Acellular animal-derived products market revenue estimates and forecasts, 2021 – 2033 (USD Million)
4.5. Synthetic Skin Substitute
4.5.1. Synthetic skin substitute market revenue estimates and forecasts, 2021 – 2033 (USD Million)
Chapter 5. Skin Substitutes Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Skin Substitutes Market: Application Movement Analysis, 2025 & 2033 (USD Million)
5.3. Global Skin Substitutes Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
5.4. Acute Wounds
5.4.1. Acute wounds market revenue estimates and forecasts, 2021 – 2033 (USD Million)
5.5. Chronic Wounds
5.5.1. Chronic wounds market revenue estimates and forecasts, 2021 – 2033 (USD Million)
Chapter 6. Skin Substitutes Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Skin Substitutes Market: End Use Movement Analysis, 2025 & 2033 (USD Million)
6.3. Global Skin Substitutes Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Hospitals
6.4.1. Hospitals market revenue estimates and forecasts, 2021 – 2033 (USD Million)
6.5. Outpatient facilities
6.5.1. Outpatient facilities market revenue estimates and forecasts, 2021 – 2033 (USD Million)
6.6. Research and manufacturing
6.6.1. Research and manufacturing market revenue estimates and forecasts, 2021 – 2033 (USD Million)
Chapter 7. Skin Substitutes Market: Regional Estimates & Trend Analysis by Product, Application, and End Use
7.1. Regional Dashboard
7.2. Market Size and Trend Analysis, 2021 to 2033
7.3. North America
7.3.1. North America skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.3.2. U.S.
7.3.2.1. Key country dynamics
7.3.2.2. Competitive scenario
7.3.2.3. Regulatory framework
7.3.2.4. Reimbursement scenario
7.3.2.5. U.S. skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.3.3. Canada
7.3.3.1. Key country dynamics
7.3.3.2. Competitive scenario
7.3.3.3. Regulatory framework
7.3.3.4. Reimbursement scenario
7.3.3.5. Canada skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.3.4. Mexico
7.3.4.1. Key country dynamics
7.3.4.2. Competitive scenario
7.3.4.3. Regulatory framework
7.3.4.4. Reimbursement scenario
7.3.4.5. Mexico skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4. Europe
7.4.1. Europe skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.2. UK
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Regulatory framework
7.4.2.4. Reimbursement scenario
7.4.2.5. UK skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.3. Germany
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Regulatory framework
7.4.3.4. Reimbursement scenario
7.4.3.5. Germany skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.4. France
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Regulatory framework
7.4.4.4. Reimbursement scenario
7.4.4.5. France skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.5. Italy
7.4.5.1. Key country dynamics
7.4.5.2. Competitive scenario
7.4.5.3. Regulatory framework
7.4.5.4. Reimbursement scenario
7.4.5.5. Italy skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.6. Spain
7.4.6.1. Key country dynamics
7.4.6.2. Competitive scenario
7.4.6.3. Regulatory framework
7.4.6.4. Reimbursement scenario
7.4.6.5. Spain skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Competitive scenario
7.4.7.3. Regulatory framework
7.4.7.4. Reimbursement scenario
7.4.7.5. Sweden skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Competitive scenario
7.4.8.3. Regulatory framework
7.4.8.4. Reimbursement scenario
7.4.8.5. Denmark skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.4.9. Norway
7.4.9.1. Key country dynamics
7.4.9.2. Competitive scenario
7.4.9.3. Regulatory framework
7.4.9.4. Reimbursement scenario
7.4.9.5. Norway skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Regulatory framework
7.5.2.4. Reimbursement scenario
7.5.2.5. China skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.5.3. Japan
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Regulatory framework
7.5.3.4. Reimbursement scenario
7.5.3.5. Japan skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.5.4. India
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Regulatory framework
7.5.4.4. Reimbursement scenario
7.5.4.5. India skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Regulatory framework
7.5.5.4. Reimbursement scenario
7.5.5.5. South Korea skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.5.6. Australia
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Regulatory framework
7.5.6.4. Reimbursement scenario
7.5.6.5. Australia skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.5.7. Thailand
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Regulatory framework
7.5.7.4. Reimbursement scenario
7.5.7.5. Thailand skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.6. Latin America
7.6.1. Latin America skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.6.2. Brazil
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Regulatory framework
7.6.2.4. Reimbursement scenario
7.6.2.5. Brazil skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Regulatory framework
7.6.3.4. Reimbursement scenario
7.6.3.5. Argentina skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.7. Middle East and Africa
7.7.1. Middle East and Africa skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.7.2. South Africa
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Regulatory framework
7.7.2.4. Reimbursement scenario
7.7.2.5. South Africa skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Regulatory framework
7.7.3.4. Reimbursement scenario
7.7.3.5. Saudi Arabia skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.7.4. UAE
7.7.4.1. Key country dynamics
7.7.4.2. Competitive scenario
7.7.4.3. Regulatory framework
7.7.4.4. Reimbursement scenario
7.7.4.5. UAE skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key country dynamics
7.7.5.2. Competitive scenario
7.7.5.3. Regulatory framework
7.7.5.4. Reimbursement scenario
7.7.5.5. Kuwait skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Market Share Analysis, 2025
8.4. Company Heat Map Analysis
8.5. Strategy Mapping
8.5.1. Expansion
8.5.2. Mergers & Acquisition
8.5.3. Partnerships & Collaborations
8.5.4. New Technology Launches
8.5.5. Research And Development
8.5.6. Company Profiles
8.5.7. Organogenesis, Inc.
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic initiatives
8.5.8. PolyNovo Limited
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Integra LifeSciences Corporation
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic initiatives
8.5.10. Smith+Nephew
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic initiatives
8.5.11. Tissue Regenix
8.5.11.1. Company overview
8.5.11.2. Financial performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic initiatives
8.5.12. RenovoDerm (ParaGen Technologies)
8.5.12.1. Company overview
8.5.12.2. Financial performance
8.5.12.3. Product Benchmarking
8.5.12.4. Strategic initiatives
8.5.13. MIMEDX Group, Inc.
8.5.13.1. Company overview
8.5.13.2. Financial performance
8.5.13.3. Product Benchmarking
8.5.13.4. Strategic initiatives
8.5.14. Essity Health & Medical. (Essity Aktiebolag (publ))
8.5.14.1. Company overview
8.5.14.2. Financial performance
8.5.14.3. Product Benchmarking
8.5.14.4. Strategic initiatives
8.5.15. Stryker
8.5.15.1. Company overview
8.5.15.2. Financial performance
8.5.15.3. Product Benchmarking
8.5.15.4. Strategic initiatives
8.5.16. Vericel Corporation
8.5.16.1. Company overview
8.5.16.2. Financial performance
8.5.16.3. Product Benchmarking
8.5.16.4. Strategic initiatives
8.5.17. BioTissue (BioStem Technologies)
8.5.17.1. Company overview
8.5.17.2. Financial performance
8.5.17.3. Product Benchmarking
8.5.17.4. Strategic initiatives
8.5.18. PolyMedics Innovations GmbH
8.5.18.1. Company overview
8.5.18.2. Financial performance
8.5.18.3. Product Benchmarking
8.5.18.4. Strategic initiatives
8.5.19. GUNZE LIMITED
8.5.19.1. Company overview
8.5.19.2. Financial performance
8.5.19.3. Product Benchmarking
8.5.19.4. Strategic initiatives
8.5.20. Zimmer Biomet
8.5.20.1. Company overview
8.5.20.2. Financial performance
8.5.20.3. Product Benchmarking
8.5.20.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 3 North America skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 4 North America skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 5 U.S. skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 6 U.S. skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 7 U.S. skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 8 Canada skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 9 Canada skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 10 Canada skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 11 Mexico skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 12 Mexico skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 13 Mexico skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 14 Europe skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 15 Europe skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 16 Europe skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 17 Germany skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 18 Germany skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 19 Germany skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 20 UK skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 21 UK skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 22 UK skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 23 France skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 24 France skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 25 France skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 26 Italy skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 27 Italy skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 28 Italy skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 29 Spain skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 30 Spain skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 31 Spain skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 32 Denmark skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 33 Denmark skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 34 Denmark skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 35 Sweden skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 36 Sweden skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 37 Sweden skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 38 Norway skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 39 Norway skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 40 Norway skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 41 Asia Pacific skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 42 Asia Pacific skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 43 Asia Pacific skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 44 China skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 45 China skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 46 China skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 47 India skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 48 India skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 49 India skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 50 Japan skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 51 Japan skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 52 Japan skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 53 Australia skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 54 Australia skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 55 Australia skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 56 South Korea skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 57 South Korea skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 58 South Korea skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 59 Thailand skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 60 Thailand skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 61 Thailand skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 62 Latin America skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 63 Latin America skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 64 Latin America skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 65 Brazil skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 66 Brazil skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 67 Brazil skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 68 Argentina skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 69 Argentina skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 70 Argentina skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 71 MEA skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 72 MEA skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 73 MEA skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 74 South Africa skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 75 South Africa skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 76 South Africa skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 77 Saudi Arabia skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 78 Saudi Arabia skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 79 Saudi Arabia skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 80 UAE skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 81 UAE skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 82 UAE skin substitutes market, by end use, 2021 – 2033 (USD Million)
Table 83 Kuwait skin substitutes market, by product, 2021 – 2033 (USD Million)
Table 84 Kuwait skin substitutes market, by application, 2021 – 2033 (USD Million)
Table 85 Kuwait skin substitutes market, by end use, 2021 – 2033 (USD Million)

List of Figures

Fig. 1 Skin substitutes market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Data analysis models
Fig. 5 Market formulation and validation
Fig. 6 Data validating & publishing
Fig. 7 Market snapshot
Fig. 8 Segment snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Skin substitutes market size and growth prospects (USD Million)
Fig. 11 Skin substitutes market: Industry Value Chain Analysis
Fig. 12 Skin substitutes market: Market Dynamics
Fig. 13 Skin substitutes market: PORTER’s Analysis
Fig. 14 Skin substitutes market: PESTEL Analysis
Fig. 15 Skin substitutes market share by product, 2025 & 2033 (USD Million)
Fig. 16 Skin substitutes market, by product: market share, 2025 & 2033
Fig. 17 Biological skin substitute market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 18 Human donor tissue-derived products market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 19 Acellular animal-derived products market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 20 Synthetic skin substitute market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 21 Skin substitutes market share by application, 2025 & 2033 (USD Million)
Fig. 22 Skin substitutes market, by application: market share, 2025 & 2033
Fig. 23 Acute wounds market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 24 Chronic wounds market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 25 Skin substitutes market share by end use, 2025 & 2033 (USD Million)
Fig. 26 Skin substitutes market, by end use: market share, 2025 & 2033
Fig. 27 Hospitals market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 28 Outpatient Facilities market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 29 Research and Manufacturing market estimates & forecasts, 2021 – 2033 (Revenue, USD Million)
Fig. 30 Regional marketplace: key takeaways
Fig. 31 North America skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 32 U S skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 33 Canada skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 34 Mexico skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 35 Europe skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 36 UK skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 37 Germany skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 38 France skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 39 Italy skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 40 Spain skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 41 Sweden skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 42 Denmark skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 43 Norway skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 44 Asia Pacific skin substitutes market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 45 China skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 46 Japan skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 47 India skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 48 South Korea skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 49 Australia skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 50 Thailand skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 51 Latin America skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 52 Brazil skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 53 Argentina skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 54 MEA skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 55 South Africa skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 56 Saudi Arabia skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 57 UAE skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 58 Kuwait skin substitutes market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 59 Key company categorization
Fig. 60 Company market positioning
Fig. 61 Key company market share analysis, 2025
Fig. 62 Strategic framework


    お問い合わせ

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    お問合せレポート

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    SEMABIZのプライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    inquiry(at)semabiz.co.jp


    関連記事